| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
701.66(B) |
| Last
Volume: |
2,008,266 |
Avg
Vol: |
3,289,637 |
| 52
Week Range: |
$390.35 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
644,570 |
871,420 |
3,176,506 |
6,211,418 |
| Total Sell Value |
$465,524,857 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
8 |
14 |
47 |
89 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-30 |
4 |
S |
$465.52 |
$76,744,390 |
D/D |
(164,125) |
101,028,810 |
|
-28% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-29 |
4 |
S |
$465.08 |
$20,517,137 |
D/D |
(44,115) |
101,192,935 |
|
-28% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-28 |
4 |
S |
$465.32 |
$5,473,168 |
D/D |
(11,760) |
101,237,050 |
|
-24% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-22 |
4 |
S |
$455.44 |
$49,153,574 |
D/D |
(107,022) |
101,248,810 |
|
-24% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-21 |
4 |
S |
$454.08 |
$14,284,313 |
D/D |
(31,454) |
101,355,832 |
|
-24% |
|
| Luciano Juan R |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$14,462 |
D/D |
32 |
15,021 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$9,943 |
D/D |
22 |
977 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$11,299 |
D/D |
25 |
53,210 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$9,943 |
D/D |
22 |
71,174 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-20 |
4 |
S |
$454.08 |
$15,509,556 |
D/D |
(34,156) |
101,387,286 |
|
-26% |
|
| Johnson Kimberly H |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$9,491 |
D/D |
21 |
2,120 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-06-20 |
4 |
A |
$451.95 |
$4,971 |
D/D |
11 |
1,674 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-06-15 |
4 |
S |
$454.14 |
$12,422,248 |
D/D |
(27,353) |
101,446,457 |
|
-31% |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-06-15 |
4 |
AS |
$448.00 |
$737,856 |
D/D |
(1,647) |
30,114 |
|
31% |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-06-14 |
4 |
AS |
$444.29 |
$731,746 |
D/D |
(1,647) |
31,761 |
|
29% |
|
| Rau Diogo |
EVP & CIDO |
• – – |
2023-06-01 |
4 |
D |
$429.46 |
$1,223,102 |
D/D |
(2,848) |
7,846 |
|
- |
|
| Rau Diogo |
EVP & CIDO |
• – – |
2023-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,300 |
10,694 |
|
- |
|
| Jonsson Patrik |
EVP&Pres, LLY Imm, LLY USA&CCO |
• – – |
2023-06-01 |
4 |
AS |
$429.46 |
$2,576,760 |
D/D |
(6,000) |
36,941 |
|
33% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2023-05-19 |
4 |
S |
$442.30 |
$86,024,241 |
D/D |
(194,354) |
101,473,810 |
|
-23% |
|
| Fyrwald J Erik |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$9,994 |
D/D |
23 |
70,972 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$4,780 |
D/D |
11 |
1,659 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$9,559 |
D/D |
22 |
2,094 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$11,297 |
D/D |
26 |
53,051 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$14,339 |
D/D |
33 |
14,951 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-05-15 |
4 |
A |
$434.51 |
$9,994 |
D/D |
23 |
953 |
|
- |
|
1437 Records found
|
|
Page 6 of 58 |
|
|
8.64 (1.19%) 
